P2X4 receptors of microglia in neuropathic pain.

Abstract

We have learned various data on the role of purinoceptors (P2X4, P2X7, P2Y6 and P2Y12 receptors) expressed in spinal microglia and several factors that presumably activate microglia in neuropathic pain after peripheral nerve injury. Especially P2X4 receptors (P2X4Rs) make a critical contribution to the pain processing. P2X4Rs of microglia might be promising targets for treating neuropathic pain. A predicted therapeutic benefit of interfering with microglial P2X4Rs may be that normal pain sensitivity would be unaffected since expression or activity of most of these receptors are upregulated or enhanced predominantly in activated microglia in the spinal cord where damaged sensory fibers project. Recently, we found that CCL21 regulates the expression of P2X4Rs in different manners, respectively. These new findings also provide novel targets for developing anti-neuropathic pain medicines.

• Authors: Kazuhide Inoue, Makoto Tsuda
• Journal: CNS & neurological disorders drug targets (CNS Neurol Disord Drug Targets) Vol. 11 Issue 6 Pg. 699-704 (Sep 2012) ISSN: 1996-3181 [Electronic] United Arab Emirates
• PMID: 22963435 (Publication Type: Journal Article)

Chemical References

• Chemokine CCL21
• Receptors, Purinergic P2X4

Topics

• Animals
• Chemokine CCL21 (metabolism)
• Humans
• Microglia (metabolism)
• Molecular Targeted Therapy
• Neuralgia (drug therapy, metabolism)
• Peripheral Nerve Injuries (drug therapy, metabolism)
• Receptors, Purinergic P2X4 (metabolism, physiology)
• Spinal Cord (metabolism)
• Up-Regulation